Sugi Predict

Sugi Predict / Compounds / SCHEMBL1768449

SCHEMBL1768449

SCHEMBL1768449

CN(C)C(=O)CC[C@H](N)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 2/20 0.58
▸ GRM8 O00222 1/20 0.58
▸ GRM6 O15303 1/20 0.58
▸ GRIN2D O15399 1/20 0.58
▸ GRIN3B O60391 1/20 0.58
▸ CYP1A2 P05177 1/20 0.58
▸ GRIK1 P39086 1/20 0.58
▸ GRM5 P41594 1/20 0.58
▸ GRIA1 P42261 1/20 0.58
▸ GRIA2 P42262 1/20 0.58
▸ GRIA3 P42263 1/20 0.58
▸ SLC1A3 P43003 1/20 0.58
▸ SLC1A2 P43004 1/20 0.58
▸ SLC1A1 P43005 1/20 0.58
▸ GRIA4 P48058 1/20 0.58
▸ GRIN1 Q05586 1/20 0.58
▸ GRIN2A Q12879 1/20 0.58
▸ GRIK2 Q13002 1/20 0.58
▸ GRIK3 Q13003 1/20 0.58
▸ GRIN2B Q13224 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL197385 1.00 GSR (0.58) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL31370269 0.86 GSR (0.53) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL22598251 0.85 GLO1 (0.58) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL27872483 0.83 GSR (0.54) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL13913806 0.83 DPP4 (0.44) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL13913822 0.83 DPP4 (0.44) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL1768346 0.80 GRM8 (0.55) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL9089892 0.80 GSR (0.50) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL1768348 0.80 GRM8 (0.55) GSRGRM8GRM6GRIN2DGRIN3B
SCHEMBL9089886 0.80 GSR (0.50) GSRGRM8GRM6GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720087-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR Zealand Pharma A/S (DK) 2026-04-08 — — EP disclosed
CN-121588081-A Application of compound 653-47 hydrochloride in preparation of medicine for treating cerebral arterial thrombosis 皖南医学院第一附属医院（皖南医学院弋矶山医院） 2026-03-03 — — CN disclosed
US-12415835-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-16 — — US disclosed
US-20250152658-A1 CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA MERCK SHARP & DOHME LLC (US) 2025-05-15 — — US disclosed
WO-2024246269-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR ZEALAND PHARMA A/S (DK) 2024-12-05 — — WO disclosed
EP-4471049-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR Zealand Pharma A/S (DK) 2024-12-04 — — EP disclosed
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY MERCK SHARP & DOHME LLC 2024-08-29 — — US disclosed
CN-118256591-A Cyclic peptide compound having high membrane permeability and library comprising same 中外制药株式会社 2024-06-28 — — CN disclosed
CN-110869544-B Cyclic peptide compound having high membrane permeability and library comprising same 中外制药株式会社 2024-03-08 — — CN disclosed
US-11891457-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-06 — — US disclosed
US-8754038-B2 Template-fixed peptidomimetics with CCR10 antagonistic activity POLYPHOR AG (CH) 2014-06-17 — — US disclosed
WO-2013100132-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD 中外製薬株式会社 (JP) 2013-07-04 — — WO disclosed
US-20120283168-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY POLYPHOR AG (CH) 2012-11-08 — — US disclosed
CN-102712676-A Template-fixed peptidomimetics with CCR10 antagonistic activty POLYPHOR AG 2012-10-03 — — CN disclosed
EP-2501715-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY Polyphor Ag (CH) 2012-09-26 — — EP disclosed
WO-2011060937-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVTY POLYPHOR AG (CH) 2011-05-26 — — WO disclosed
US-20080269212-A1 Amino acid derivatives of indolinone based protein kinase inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2008-10-30 — — US disclosed
EP-0543997-B1 DERIVATIVES OF METHOTREXATE WITH ANTIRHEUMATIC ACTIVITY CHUGAI PHARMACEUTICAL CO LTD (JP) 1999-12-08 — — EP disclosed
US-5354753-A Methotrexate derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 1994-10-11 — — US disclosed
EP-0543997-A1 NOVEL METHOTREXATE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 1993-06-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891457-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R GSR 4333/4885GRM8 3522/4885GRM6 2967/4885
US-20120283168-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CCR10 ANTAGONISTIC ACTIVITY CCR10, CCR1, CCRL2 GSR 4018/4885GRM8 1650/4885GRM6 1857/4885
US-20240287138-A1 CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY TNF, TNFRSF1A, CD40 GSR 4340/4885GRM8 3419/4885GRM6 3366/4885
US-20080269212-A1 Amino acid derivatives of indolinone based protein kinase inhibitors PHKG1, MAP3K20, MKNK1 GSR 4223/4885GRM8 2519/4885GRM6 1552/4885
US-12415835-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R GSR 4333/4885GRM8 3522/4885GRM6 2967/4885
US-20250152658-A1 CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA IL1R1, IL1A, IL1B GSR 2126/4885GRM8 4512/4885GRM6 4682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.